SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools
Novel animal models for diabetes complications
WP4 aims at:
-
Characterizing existing animal models of type 1 and type 2 diabetes for developing diabetic nephropathy, retinopathy and cardiovascular disease.
-
Generating novel animal models of type 1 and type 2 diabetes that reproduce micro- and macrovascular complications as observed in humans.
-
Generating new animal models based on candidate genes and biomarkers identified by SUMMIT discovery platform.
The established animal models will enable SUMMIT to predict key pathogenetic mechanisms of diabetes chronic vascular complications as well as the development of new therapies.
Work Package 4 (WP4)
MISSION
To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
-
the identification of patients at high risk of diabetes complications
-
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.
Related Sites
